Avantor Investor Day Presentation Deck

Significant Biopharma exposure BIOPHARMA EDUCATION & GOVERNMENT HEALTHCARE END MARKET EXPOSURE ADVANCED TECHNOLOGIES & APPLIED MATERIALS Navantor™ % Avantor¹ LT Growth Rate 50% 15% 10% 25% HSD LSD MSD MSD BIOPHARMA EXPOSURE BIOPRODUCTION 1. Based on FY20 actuals 2. Growth in Bioproduction order book from end of 2019 to end of Q2 2021 O CLINICAL & BIOREPOSITORY SERVICES RESEARCH & DISCOVERY Attractive growth driven by bioproduction 5X growth in production orders since 2019² Superior gross margins in production (~50%-80%) Biopharma exposure provides strong annual growth base for Avantor 73

View entire presentation